Xinqiang Han is a Cardiology physician. OpenAlex indexes 25 publications with 750 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 Reid Pkwy
Suite 210
Richmond, IN 473741157
Telephone
765-962-1337Registry record last updated 4 May 2016.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20258 payments
- Boston Scientific CorporationProgram year20253 payments
- PFIZER INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.4%Beta blocker33.1%Metoprolol Succinate29%Sotalol29%Metoprolol Tartrate22%Carvedilol11%Atenolol9%Part D≥61 patientsAntiarrhythmic11.5%Amiodarone Hcl73%Flecainide Acetate18%Multaq9%Part D<11 patients+ 9 more classes in this area
Blood & clotting
24.1%Factor Xa inhibitor17.5%Eliquis86%Xarelto14%Part D<11 patientsP2Y12 inhibitor3.9%Clopidogrel100%Part D≥25 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.1%Potassium supplement1.8%Potassium Chloride64%Klor-Con M2036%Part D<11 patientsSGLT2 inhibitor1.3%Jardiance54%Farxiga46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Percutaneous Left Atrial Appendage Occlusion Therapy: Evolution and Growing Evidence
Reviews in Cardiovascular Medicine
2023 - Percutaneous Left Atrial Appendage Occlusion Therapy: Past, Present, and Future
Cardiovascular Innovations and Applications
2023 - Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion
Clinical Interventions in Aging
2021 - Ventricular fibrillation in congenitally corrected transposition of great arteries treated with pacing: a case report
European Heart Journal - Case Reports
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”